First American Corporation (The) (FAF) stock prices updated...
 

First American Corporation (The) stock price

First American Corporation (The) latest news:


  • 08/30/2017 06:15:02

    Shares of Jack Daniel's parent Brown-Forman rise premarket after company's better-than-expected Q1 earnings report

    Shares of alcohol company Brown-Forman Corp. were up 1.6% in premarket trade on Wednesday after the company reported fiscal 2018 first-quarter earnings that were above Wall Street's expectations. The company said net income of $178 million, or 46 cents earnings per share, compared with $144 million, or 36 cents per share during the same period a year ago. FactSet's consensus for per-share earnings was 39 cents. Brown-Forman revenue was $723 million, compared with $661 million a year ago, and above FactSet's $687 million revenue consensus. "We continue to foresee growth potential for our brands, most notably in American whiskey," said Brown-Forman Chief Executive Paul Varga in a statement. Brown-Forman said it expects underlying net sales to grow in the range of 4% to 5% for the full year, thanks to new Jack Daniel's whiskies. The company also forecasts per-share earnings to be in the range of $1.85 to $1.95, which puts FactSet's $1.85 consensus at the lower end. Shares of Brown-Forman have gained 14% in the year to date, while the S&P 500 index is up more than 9% in the year.Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

  • 08/07/2017 05:34:22

    MyoKardia shares surge 32% on positive mid-stage trial results for heart muscle disease

    MyoKardia Inc. shares surged 31.8% in premarket trade Monday on positive mid-stage clinical trial results for its mavacamten therapy. Patients on the therapy met the trial's primary endpoint and key secondary endpoints in the phase 2 trial, the company said. MyoKardia expects to start its next clinical trial by the end of this year, depending on discussions with the Food and Drug Administration. The latest data came from the clinical trial's first patient cohort, in which 11 patients were enrolled and 10 patients completed the study. The one patient in question had a history of atrial fibrillation and experienced an episode of atrial fibrillation during the trial. All other safety problems were mild to moderate, according to MyoKardia, and "a majority of the [adverse events] were deemed to be unrelated to the study drug." The Independent Data Monitoring Committee reviewed the trial's safety data and recommended the study be continued, the company said. Mavacamten is intended for symptomatic, obstructive hypertrophic cardiomyopathy, which occurs when heart muscle cells enlarge and block blood flow, and is a common cause of sudden cardiac arrest, according to the American Heart Association. MyoKardia shares have surged 20.4% over the last three months, compared with a 3.2% rise in the S&P 500 .Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

  • 08/07/2017 05:25:28

    MyoKardia shares surge 17% on positive mid-stage trial results for heart muscle disease

    MyoKardia Inc. shares surged 16.6% in premarket trade Monday on positive mid-stage clinical trial results for its mavacamten therapy. Patients on the therapy met the trial's primary endpoint and key secondary endpoints in the phase 2 trial, the company said. MyoKardia expects to start its next clinical trial by the end of this year, depending on discussions with the Food and Drug Administration. The latest data came from the clinical trial's first patient cohort, in which 11 patients were enrolled and 10 patients completed the study. The one patient in question had a history of atrial fibrillation and experienced an episode of atrial fibrillation during the trial. All other safety problems were mild to moderate, according to MyoKardia, and "a majority of the [adverse events] were deemed to be unrelated to the study drug." The Independent Data Monitoring Committee reviewed the trial's safety data and recommended the study be continued, the company said. Mavacamten is intended for symptomatic, obstructive hypertrophic cardiomyopathy, which occurs when heart muscle cells enlarge and block blood flow, and is a common cause of sudden cardiac arrest, according to the American Heart Association. MyoKardia shares have surged 20.4% over the last three months, compared with a 3.2% rise in the S&P 500 .Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

  • 07/31/2017 23:03:37

    Did Alexander Hamilton hold this coin?

    Researcher says he has identified silver coin as first American coin ever made

  • 07/17/2017 20:38:54

    U.S. makes lower trade deficit top priority in NAFTA talks

    WASHINGTON (Reuters) - The United States on Monday launched the first salvo in the renegotiation of the 23-year-old North American Free Trade Agreement (NAFTA), saying its top priority for the talks was shrinking the U.S. trade deficit with Canada and Mexico.

  • 07/17/2017 20:37:20

    CORRECTED-UPDATE 2-U.S. makes lower trade deficit top priority in NAFTA talks

    WASHINGTON, July 17 (Reuters) - The United States on Monday launched the first salvo in the renegotiation of the 23-year-old North American Free Trade Agreement (NAFTA), saying its top priority for the talks was shrinking the U.S. trade deficit with Canada and Mexico.

  • 07/12/2017 18:18:44

    Dana Canedy, Former Times Editor, Will Administer the Pulitzers

    Ms. Canedy, a former senior editor at The Times who shared a Pulitzer Prize in 2001, will be the first woman and the first African-American to steer the awards process.

  • More trends:

    First BanCorp.FBP | First BanksFBS^A | First Commonwealth Financial CorporationFCF | First Horizon National CorporationFHN | First Horizon National CorporationFHN^A | First Industrial Realty TrustFR | First Majestic Silver Corp.AG | First Marblehead Corporation (The)FMD | First Niagara Financial Group Inc.FNFG^B | First Potomac Realty TrustFPO |